Published in Antimicrob Agents Chemother on December 01, 1998
Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev (2002) 3.27
In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol (1998) 2.13
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2003) 1.92
Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology (2012) 1.83
Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother (2006) 1.72
Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines. J Acquir Immune Defic Syndr (2013) 1.56
Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother (2002) 1.54
HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J Biol Chem (2009) 1.47
HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J Am Chem Soc (2008) 1.43
Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J Virol (2010) 1.39
Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa. Pediatr Infect Dis J (2011) 1.30
Molecular Basis for Drug Resistance in HIV-1 Protease. Viruses (2010) 1.20
Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol (2005) 1.16
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. AIDS Rev (2000) 1.15
Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One (2011) 1.11
Current and Novel Inhibitors of HIV Protease. Viruses (2009) 1.10
Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol (2004) 1.08
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. HIV Seq Compend (2001) 0.98
In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother (2002) 0.98
Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag (2008) 0.97
Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. J Med Chem (2007) 0.97
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study. Antimicrob Agents Chemother (2011) 0.96
Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother (2006) 0.94
Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitors. J Phys Chem B (2010) 0.91
Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir. Antimicrob Agents Chemother (2004) 0.90
Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients. Br J Clin Pharmacol (2005) 0.89
Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir. Protein Sci (2008) 0.88
Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. Br J Clin Pharmacol (2009) 0.88
Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther Clin Risk Manag (2005) 0.87
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Antimicrob Agents Chemother (2007) 0.86
Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation. ACS Med Chem Lett (2012) 0.86
Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process. Mol Biol Int (2012) 0.85
Drug Interactions with Antiretrovirals. Curr Infect Dis Rep (2000) 0.84
The progress made in determining the Mycobacterium tuberculosis structural proteome. Proteomics (2011) 0.83
HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl) (2015) 0.82
Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: free energy calculation and molecular dynamic simulation. J Mol Model (2009) 0.82
Testing the substrate-envelope hypothesis with designed pairs of compounds. ACS Chem Biol (2013) 0.81
CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir. Drug Metab Dispos (2011) 0.81
Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells. AIDS Res Hum Retroviruses (2010) 0.80
Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients. Clin Pharmacokinet (2014) 0.80
Targeting RNA-protein interactions within the human immunodeficiency virus type 1 lifecycle. Biochemistry (2013) 0.80
Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. Ther Drug Monit (2008) 0.80
Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir. Int J Infect Dis (2013) 0.79
Computational methods in drug discovery. Beilstein J Org Chem (2016) 0.78
P1 and P1' para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease. J Mol Graph Model (2013) 0.78
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742. Antimicrob Agents Chemother (2008) 0.77
Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen. PLoS One (2011) 0.77
Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors. Future Med Chem (2011) 0.76
High-Throughput Excipient Discovery Enables Oral Delivery of Poorly Soluble Pharmaceuticals. ACS Cent Sci (2016) 0.75
Simple, Rapid and Validated LC Determination of Lopinavir in Rat Plasma and its Application in Pharmacokinetic Studies. Sci Pharm (2011) 0.75
Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen. AIDS Res Ther (2005) 0.75
Targeting cancer stem cells expressing an embryonic signature with anti-proteases to decrease their tumor potential. Cell Death Dis (2013) 0.75
Initial antiretroviral regimens. BMJ (2002) 0.75
New Drugs for the Treatment of HIV Infection. Curr Infect Dis Rep (2001) 0.75
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods (1988) 7.74
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet (1998) 4.54
Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science (1990) 4.01
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A (1995) 3.18
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med (1995) 3.04
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother (1997) 2.57
Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther (1996) 2.43
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1991) 2.16
In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol (1998) 2.13
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (1997) 2.08
A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS (1996) 2.03
Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology (1998) 1.77
Therapy for human immunodeficiency virus infection. N Engl J Med (1993) 1.61
Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J Med Chem (1991) 1.50
Evaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors. J Biol Chem (1979) 1.33
Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere. Structure (1995) 1.10
A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease. J Med Chem (1996) 1.09
Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J Med Chem (1998) 0.97
In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification. Drug Metab Dispos (1999) 0.91
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
TRANSFAC: an integrated system for gene expression regulation. Nucleic Acids Res (2000) 15.70
The TRANSFAC system on gene expression regulation. Nucleic Acids Res (2001) 13.63
ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell (2000) 9.13
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Expanding the TRANSFAC database towards an expert system of regulatory molecular mechanisms. Nucleic Acids Res (1999) 6.70
A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet (1996) 6.58
Natural engineering principles of electron tunnelling in biological oxidation-reduction. Nature (1999) 6.38
Revealing the maximum strength in nanotwinned copper. Science (2009) 6.27
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol (1998) 5.54
Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet (1998) 5.46
Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3) Nature (1996) 5.32
Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest (1994) 5.12
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08
Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A (1996) 4.76
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet (1998) 4.54
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother (1986) 4.51
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol (1996) 4.47
Cdc25 cell-cycle phosphatase as a target of c-myc. Nature (1996) 4.23
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
Development of microsatellite markers and characterization of simple sequence length polymorphism (SSLP) in rice (Oryza sativa L.). Mol Gen Genet (1996) 3.75
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis (1998) 3.69
CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med (2000) 3.62
Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol (1998) 3.61
Accumulation, metabolism, and effects of organochlorine insecticides on microorganisms. Microbiol Rev (1982) 3.49
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol (1994) 3.45
Functionalized graphene sheets for polymer nanocomposites. Nat Nanotechnol (2008) 3.45
Do general practitioners know when living wills are legal? J R Coll Physicians Lond (1998) 3.39
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS (2001) 3.35
SVM-Prot: Web-based support vector machine software for functional classification of a protein from its primary sequence. Nucleic Acids Res (2003) 3.34
Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am J Respir Cell Mol Biol (1994) 3.32
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J (1996) 3.22
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A (1995) 3.18
Structure of the Trg protein: Homologies with and differences from other sensory transducers of Escherichia coli. Proc Natl Acad Sci U S A (1984) 3.13
Regulation of CSF1 promoter by the SWI/SNF-like BAF complex. Cell (2001) 3.10
Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J (2001) 3.08
Modulation of flagellar expression in Escherichia coli by acetyl phosphate and the osmoregulator OmpR. J Bacteriol (1995) 3.06
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol (1995) 3.05
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med (1995) 3.04
Nucleotide sequence of the structural genes for an anion pump. The plasmid-encoded arsenical resistance operon. J Biol Chem (1986) 2.97
Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol (1993) 2.96
Evolutionarily conserved sequences on human chromosome 21. Genome Res (2001) 2.95
Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int (2007) 2.92
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology (2003) 2.88
Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet (1998) 2.85
Estimating spatio-temporal receptive fields of auditory and visual neurons from their responses to natural stimuli. Network (2001) 2.85
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst (1998) 2.85
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science (1990) 2.83
Effect on mortality of community-based maternity-care programme in rural Bangladesh. Lancet (1991) 2.82
Modulation of polyketide synthase activity by accessory proteins during lovastatin biosynthesis. Science (1999) 2.82
Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest (1992) 2.80
An information-based sequence distance and its application to whole mitochondrial genome phylogeny. Bioinformatics (2001) 2.80
Parallel genotyping of human SNPs using generic high-density oligonucleotide tag arrays. Genome Res (2000) 2.79
Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab (2001) 2.79
Filamentous growth of Candida albicans in response to physical environmental cues and its regulation by the unique CZF1 gene. Mol Microbiol (1999) 2.74
Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res (1995) 2.72
Tired, weak, or in need of rest: fatigue among general practice attenders. BMJ (1990) 2.70
Mutations in NADH:ubiquinone oxidoreductase of Escherichia coli affect growth on mixed amino acids. J Bacteriol (1994) 2.68
The forgotten serine. A critical role for Ser-2035.42 in ligand binding to and activation of the beta 2-adrenergic receptor. J Biol Chem (2000) 2.67
Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest (1991) 2.65
Perceived discrimination and early substance abuse among American Indian children. J Health Soc Behav (2001) 2.60
Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. Cancer Res (2001) 2.60
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci U S A (1994) 2.59
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother (1997) 2.57
Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J Biol Chem (1999) 2.57
Food-based oral rehydration salt solution for acute childhood diarrhoea. Lancet (1989) 2.56
A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev (1993) 2.53
The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci (2004) 2.47
Validation and reproducibility of food frequency questionnaire for Korean genome epidemiologic study. Eur J Clin Nutr (2007) 2.46
The formation, isolation, and biological activity of a cytokinin 7-glucoside. Plant Physiol (1973) 2.44